Monitor VRAX's stock price post-split to see if it sustains above $1 and regains Nasdaq compliance. If the price fails to hold, the company may face delisting risk, which could be a negative catalyst.
Price Chart
Executive Summary
Virax Biolabs Group Ltd announced a 1-for-25 reverse share split effective June 26, 2026, aimed at regaining compliance with Nasdaq's minimum $1 bid price rule. The consolidation is a mechanical capital structure adjustment that does not alter shareholder percentage interests and has no impact on the company's underlying business or financials.
Key Facts
- Board approved a 1-for-25 share consolidation effective June 26, 2026.
- Shareholders approved the consolidation at an extraordinary general meeting on June 12, 2026.
- Objective is to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) (minimum $1 bid price).
- No fractional shares will be issued; fractional shares will be rounded up to the next whole number.
- The consolidation does not alter any shareholder's percentage interest in the company.
- Post-consolidation shares will trade under the same symbol VRAX with a new CUSIP number G9495L133.
Financial Impact
No financial figures reported; the reverse split is a mechanical adjustment with no direct financial impact.
Risk Factors
- If the stock price does not maintain above $1 after the reverse split, the company may still face delisting from Nasdaq.
- Reverse splits are often viewed negatively by the market and can lead to selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-281196 |
| Document: vrax-ex99_1.htm | 0001193125-26-281196 |
| Document: 0001193125-26-281196-index-headers.html | 0001193125-26-281196 |
| Document: 0001193125-26-281196-index.html | 0001193125-26-281196 |
| Document: 0001193125-26-281196.txt | 0001193125-26-281196 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $1.85 | awaiting T+60 | — | $1.19 (−35.68%) |
Sep 4, 2026 7w ago | 6-K | $2.63 | awaiting T+60 | — | $1.19 (+54.75%) |
Sep 4, 2026 7w ago | EFFECT | $2.63 | awaiting T+60 | — | $1.19 (−54.67%) |
Aug 18, 2026 10w ago | 6-K | $2.76 | awaiting T+60 | — | $1.19 (−56.88%) |
Jul 31, 2026 12w ago | 6-K | $2.62 $1.19 | ▲ +54.58% | ▲ +57.04% | $1.19 (+54.58%) |
Jul 16, 2026 14w ago | 6-K | $3.90 $1.87 | ▼ −52.05% | ▼ −55.76% | $1.19 (−69.49%) |
Jul 9, 2026 15w ago | Press Release | $6.36 $2.20 | ▲ +65.41% | ▲ +67.04% | $1.19 (+81.29%) |
Jul 9, 2026 15w ago | 6-K | $6.36 $2.20 | ▼ −65.41% | ▼ −67.04% | $1.19 (−81.29%) |
Jun 24, 2026 17w ago | 6-K | $0.1350 $0.0924 | ▼ −31.56% | ▼ −36.89% | $1.19 (+781.48%) |
Jun 12, 2026 19w ago | 6-K | $0.1840 $0.1092 | ▼ −40.65% | ▼ −43.44% | $1.19 (+546.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers